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Abstract 
Studies have shown that honeys from around the world can inhibit the growth of a range of 
dermatologically important microbes. As well as reports of the antimicrobial properties of 
honey, a number of recent in vitro and in vivo studies suggest that honey is able to modulate 
immunological parameters related to the skin immune system. Paradoxically, both immune-
stimulatory and anti-inflammatory effects have been observed. In this review, scientific 
research investigating the immunomodulatory properties of honeys from around the world, in 
relation to disorders of the skin, is evaluated. Whilst there is sufficient evidence to suggest 
that honey does indeed have immunomodulatory properties, which may at least partially 
explain the ability of honey to promote the healing of wounds, there are still gaps in the 
scientific knowledge and literature. More research is necessary for a more complete 
understanding of the immune modulating properties of honey and to enable the utilisation of 
honey as an immune-modulating agent in dermatology.  
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Introduction 
Traditionally, honey has been used around the world to treat skin disorders with a 
microbiological and immunological aetiology. In Ayurvedic medicine, for example, honey is 
used to treat cuts and wounds, eczema, dermatitis, burns and Fournier’s gangrene (Ediriweera 
& Premarathna, 2012; Deshpande & Kulkani, 2010). 
In modern day clinical practice, manuka honey, produced by honey bees (Apis mellifera) 
feeding on the manuka tree (Leptospermum scoparium), is applied topically in the treatment 
of wounds (Irish, Blair & Carter, 2011). It has been approved for clinical use in countries 
including; New Zealand, Australia, United States of America, Canada and the United 
Kingdom.  
A significant proportion of the world’s population suffer from skin disorders and these can 
have a great impact on quality of life (Mahler, Jackson & Ijacu, 2009). Skin disorders have 
been shown to have a variety of causes; some are associated with microbial skin invasion, 
others with exposure to irritants e.g. chemicals in cosmetics, others are immunological in 
nature and result from hypersensitivity responses to environmental allergens (Fonacier, 
Dreskin & Leung, 2010). Current treatments for some chronic skin conditions are deficient, 
for example, microbial drug resistance has hindered the effectiveness of antibiotics in the 
treatment of chronic wounds and ultraviolet radiation therapy used to treat psoriasis and 
atopic dermatitis may induce skin tumourigenesis (Gasparro, 2000). 
The skin healing properties of honey have been largely attributed to its anti-microbial 
properties; a plethora of in vitro studies have demonstrated antimicrobial activity of honeys 
from all over the world against dermatologically important microbes (Schneider, Coyle, 
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Warnock, Gow & Fyfe, 2013; Kuncic, Jaklic, Lapanje & Gunde-Cimerman, 2012; McLoone, 
Warnock & Fyfe, 2015). More recently, in vitro research has suggested that honeys of diverse 
floral origins can modulate the skin immune system; both immunostimulatory and anti-
inflammatory effects have been observed (Majtan, Kumar, Majtan, Walls & Klaudiny, 2009; 
Majtan et al, 2013). In this review, the scientific evidence for the immunomodulatory 
properties of honey in relation to disorders of the skin is evaluated and the mechanisms of the 
immunomodulatory properties explored. A principle aim was to understand more about the 
therapeutic potential of honey as a treatment for immune-mediated skin disorders.   
Immunomodulatory properties of honey  
The skin immune system plays a major role in killing skin invading microbes yet an 
overstimulated and uncontrolled immune response contributes to the pathology of a variety of 
skin disorders. During wound healing, for example, the skin immune system plays an 
important role in the eradication of pathogenic microbes and tissue repair, but unregulated 
inflammation is an important factor associated with inefficient healing in chronic wound 
infections (Bowler, 2002). The skin immune system is comprised of a complex network of 
cells, molecules and physical barriers that prevent infection and maintain skin health. Skin 
cells called keratinocytes play an important function in protecting the skin from infection and 
also play a role in the pathophysiology of certain skin diseases (Albanesi, Scarponi, 
Giustizieri & Girolomoni, 2005). Keratinocytes can recognise foreign microbes via toll-like 
receptors expressed on their surface and release cytokines and anti-microbial peptides 
(AMPs) in response. Other skin residing cells, such as, macrophages, dendritic cells, mast 
cells and circulating T cells perform immune surveillance and neutrophils and monocytes 
infiltrate the skin, for example, during infection, inflammation or wound healing.  
4 
 
Honey or its components have been shown to modulate cytokine production by a range of 
cells (Majtan et al, 2013; Tonks et al, 2003).  It may be that honey contributes to skin healing 
not only through its anti-microbial properties but by boosting the skin immune system to fight 
infection, promoting wound healing or suppressing inflammation in the skin. Knowledge of 
the immunomodulatory properties of honey would provide a greater understanding of its 
therapeutic mechanisms and may uncover innovative treatments for skin disorders that are 
immune-mediated.  
Immunomodulatory properties of honey (immune cells): in vitro studies 
Tonks, Cooper, Price, Molan & Jones (2001) reported that two New Zealand honeys; manuka 
and pasture honey significantly reduced the production of reactive oxygen intermediates 
(ROIs) by MM6 cells (a monocytic cell line). Pasture honey was found to be the most 
effective. The researchers also demonstrated that manuka and pasture honey stimulated the 
production of the cytokine tumour necrosis factor- alpha (TNF-α) by the same cells. The 
mechanisms of the honeys immunomodulatory properties were unknown but the authors 
suggested that high levels of hydrogen peroxide in the pasture honey may have induced a 
negative feedback effect on the production of ROIs by the MM6 cells. Reactive oxygen 
species are produced in abundance in chronic wounds and stimulate inflammation (Wlashek 
& Scharffetter-Kochanek, 2005). Honey could therefore be therapeutic in the treatment of 
chronic wounds by suppressing inflammation via the inhibition of ROI production. It was 
concluded that manuka and pasture honey from New Zealand have immunomodulatory 
properties and that these findings may at least partially explain the observed effects of honey 
on wound repair, particularly as TNF-α has been shown to promote macrophage activation, 
stimulate angiogenesis and re-epithelialisation during early wound healing (Barrientos, 
Stojadinovic, Golinko, Brem & Tomic-Canic, 2008).  
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Tonks et al (2003), further reported that Australian jelly bush honey and New Zealand 
manuka and pasture honey stimulated increased production of the cytokines TNF-α, IL-1β 
and IL-6 by MM6 cells and human blood monocytes. Australian jelly bush honey was found 
to be the most effective with peak cytokine levels increasing from 0 to 500 pg/ml for TNF-α, 
0 to 1300 pg/ml for IL-6 and 0 to 120 pg/ml for IL-1β. The components in the honey that 
stimulated the upregulation of cytokine production were not identified.  As the cytokines 
measured in the study are thought to play a role in wound healing, for example, IL-6 has been 
shown to enhance proliferation of keratinocytes and attract neutrophils and IL-1β stimulates 
the release of important wound healing growth factors, the authors suggested that this 
immunomodulatory effect may at least partially explain the wound healing properties of 
honey (Barrientos et al, 2008).  
Later in 2007, Tonks et al, identified a 5.8kDa component via fractionation of manuka honey 
that stimulated TNF-α cytokine production by MM6 cells, murine bone marrow derived 
macrophages (MBMDM) and human monocytes. It was demonstrated that the 5.8kDa 
component stimulated cytokine production via toll-like receptor 4 (TLR-4) as incubation with 
a blocking antibody against TLR-4 blocked the immunostimulatory effect. Also, the 5.8kDa 
component did not stimulate cytokine production in MBMDM isolated from TLR-4 knockout 
mice but did for MBMDM isolated from TLR-2 knockout mice.  
In the three publications by Tonks et al, the researchers were of the view that the 
immunomodulatory effects of the honey were not due to lipopolysaccharide (LPS) from 
contaminating bacteria, as levels in the honeys were described as low (< 1 ng/ml) in all the 
honeys used in their studies. Additionally, Tonks et al, (2007) showed that the 
immunomodulatory effects of the honey were inhibited by heat treatment; LPS is a heat 
stable compound and not affected by Polymixin B (PMB), a known inhibitor of LPS.  
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Moreover, treatment of cells with 1ng/ml LPS did not stimulate cytokine production to levels 
induced by the honey.  
However, the role of LPS in the immunomodulatory properties of honey was to become more 
controversial when Timm, Bartfelt & Hansen (2008) reported their findings of an 
investigation into the  ability of manuka honey (UMF 16+ and active 5+), Danish honey 
(Jakobsen & Hvam) and artificial honey to stimulate IL-6 production by MM6 cells and 
reactive oxygen intermediate (ROI) release from trans retinoic acid differentiated HL-60 cells 
(cells that are terminally differentiated along the neutrophil pathway and share similar 
characteristics to neutrophils). The results showed that both the manuka and the Danish 
honeys stimulated IL-6 production and ROI release suggesting the presence of an 
immunostimulatory agent in the honeys. The researchers measured the levels of LPS in the 
honeys and described the levels as substantial, no less than 69 pg/ml (0.069 ng/ml). They 
reported that the amounts of IL-6 and ROI induced by the honeys correlated with the amount 
that would be expected due to the content of LPS in the honey with correlation coefficients of 
0.99 and 0.94 respectively. Timm et al (2008) also stated that the immunostimulatory 
component in the honey was resistant to boiling and could be inhibited by the addition of 
polymixin B. The authors were of the opinion that the immunostimulatory effects of the 
honey could be solely explained by the LPS content of the honeys.  Confirmation of this 
conclusion can be obtained from the study by Moesby et al, (1999) showing that LPS levels 
as low as 3.1 pg/ml (0.0031ng/ml) can stimulate IL-6 production by MM6 cells (Moesby, 
Jensen, Hansen & Christensen 1999). 
Gannabathula et al, (2012) reported that New Zealand kanuka, manuka and clover honeys 
obtained from bees feeding on Kunzea ericoides, Leptospermum scoparium and Trifolium 
species respectively stimulated TNF-α protein production by the differentiated monocytic cell 
lines THP-1 and U937. The cells were differentiated to macrophages with phorbol 12-
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myristate 13-acetate (PMA) and TNF-α levels were measured in cell supernatant following 
treatment with honey by Enzyme Linked Immunosorbent Assay (ELISA). Kanuka honey was 
found to be the most effective honey and induced approximately 350 pg/ml TNF-α; by 
comparison, 100 ng/ml LPS produced TNF-α levels of approximately 500 pg/ml. TNF-α 
levels induced by manuka and clover honeys were less than 20% of that induced by kanuka 
honey. The authors were of the view that the concentrations of LPS in the honeys did not 
correlate with their immunostimulatory activities (kanuka honey = 2ng/ml LPS, manuka and 
clover honeys < 2ng/ml LPS). The addition of polymixin B completely inhibited the ability of 
manuka honey to stimulate TNF-α production, and reduced the ability of kanuka honey to 
stimulate TNF- α production by 80%. It was concluded that kanuka honey contains a major 
polymixin B sensitive component that is largely responsible for its immunostimulatory 
activity and a minor polymixin B insensitive component. Heating the kanuka honey reduced 
the immunostimulatory effect by 20-35% and fractionation revealed that the 
immunostimulatory activity was associated with a high molecular weight component (> 
30kDa). The researchers had previously identified type II arabinogalactans (AGPs), known 
immunostimulators with a molecular weight of approximately 110 kDa, in kanuka honey. 
Arabinogalactans are essential polysaccharide polymers found in the cell walls and tissues of 
plants and can be transported to the honey from plants by bees during the honey making 
process. The study also demonstrated the ability of AGPs to stimulate TNF-α production by 
the same cell lines with levels reaching approximately 180 pg/ml with 25µg/ml AGP. The 
immunostimulatory effects of the AGPs were found to be polymixin B sensitive and heat 
stable and levels of LPS in the purified AGPs were found to be 0.31ng /5µg AGP. The 
authors proposed that AGPs may possess a polymixin-B binding lipid moiety enabling 
polymixin B to inhibit the immunostimulatory effects of AGPs. The final conclusion was that 
AGPs are important immunostimulatory components of kanuka honey.  
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Raynaud et al (2013), reported that thyme honey provided by Melipharm
® 
(Limoges, France) 
stimulated PGE2, COX-2 and TNF-α protein production and also induced NFκB and AP-1 
activation in RAW 264.7 murine macrophages. The authors concluded that the effects of the 
honey could not be explained by the LPS content as the levels of LPS in the honey were 
insufficient to stimulate the production of these molecules to levels induced by the honey. 
Macrophages play an important role in the wound healing process by phagocytosing foreign 
material and debris in the wound bed and by producing cytokines that stimulate tissue repair 
(Nguyen, Orgill & Murphy, 2009). The authors proposed that honey induced activation of 
NF-κB and AP-1 could induce COX-2 production leading to increased PGE2 production. AP-
1 regulates gene expression of various inflammatory mediators such as inducible nitric oxide 
synthase, TNF-α and IL-1β. Honey induced upregulation of early inflammatory mediators, 
via AP-1 or NF-κB activation, may promote the early wound healing process.  
It may also be of interest to note the study of Abuharfeil, Aloran & Aboshehada (1999) 
reporting that honey produced by honey bees (Apis melifera) kept in a hive at Jordan 
University Campus farm, Jordan, stimulated the proliferation of unstimulated human B and T 
lymphocytes collected from human blood as measured by an MTT assay. The researchers 
concluded that their honey contains unidentified lymphomitogens and suggested that these 
lymphomitogens could be plant lectins obtained from plants during the honey making 
process. In relating this work to the skin it may be that honey is able to stimulate the 
proliferation of skin residing T cells although further research would be required to 
investigate this.  
Other in vitro studies have also shown anti-inflammatory effects of honey on immune cells. 
Ahmad, Khan & Mesaik (1999) reported that six different types of commercial honey (clover 
honey from USA, capilano from Australia, langanese from Germany, al-shafa, swat and 
sidder from Pakistan) purchased in a supermarket in Pakistan inhibited bovine thrombin 
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induced respiratory burst in human neutrophils and rodent peritoneal macrophages. In line 
with this, Henriques, Jackson, Cooper & Burton (2006) observed free radical quenching 
activity in three honeys of different origin (gales honey obtained from a supermarket in the 
UK and pasture and manuka honey obtained from New Zealand). These findings suggest that 
honey may be able to reduce inflammation by quenching free radicals in an inflammatory 
site. Chepulis and Francis, (2012) reported that raw manuka honey containing high levels of 
Methylglyoxal (MGO) obtained from bee keepers in the Wairapa region of New Zealand and 
supplied by Manuka Health New Zealand Ltd had contradictory effects on TNF-α production 
by neutrophils. Both the MGO250
TM
 and MGO400
TM
 manuka honey samples induced 
inhibition of TNF-α production by neutrophils when measured at honey concentrations of 
400µg/ml. Honey concentrations of 100µg/ml MGO250
TM 
stimulated TNF-α production by 
neutrophils (see table 1).  
Immunomodulatory properties of honey (skin cells): in vitro studies 
In 2009, Majtan et al reported the ability of acacia honey obtained from Slovakia to stimulate 
TNF-α, TGF-β, IL-1β and matrix metalloproteinase 9 (MMP-9) mRNA expression by human 
primary keratinocytes isolated from human foreskin. TNF-α mRNA expression was up-
regulated two-fold by the honey and TGF-β and IL-1β mRNA expression were up-regulated 
eight-fold and ten-fold respectively.  This stimulation was not thought to be due to LPS as 
LPS levels in the honey were found to be 0.42 ng/ml and 10 ng/ml of lipopolysaccharide did 
not stimulate cytokine mRNA expression in these cells. The researchers also investigated the 
ability of the honey component major royal jelly protein 1 to stimulate cytokine production 
by the same cells and found there was a significant increase in TNF-α mRNA expression and 
a non-significant increase in levels of TGF-β and IL-1β mRNA. The authors suggested that 
because keratinocytes play an important role in the production of cytokines and MMP-9 
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during early wound healing, stimulation of such molecules by honey may aid the wound 
healing process.  
Contrary to the immunostimulatory effects of honey described above Majtan et al (2013) 
reported an anti-inflammatory effect of an aqueous extract of fir honeydew honey obtained 
from an apiary in Bardejov, Slovakia. In this study, the extract inhibited TNFα induced 
matrix metalloproteinase-9 (MMP-9) protein and mRNA production by human keratinocytes 
(HaCaT) cells as measured by ELISA and RT-PCR respectively. The phenolic compounds 
kaempferol and apeginin were identified in the honey and reduced TNF-α induced MMP-9 
production in a dose dependent manner. MMP-9 is thought to play an important yet 
temporary role in normal wound healing through its involvement in re-epithelialisation and 
extra-cellular matrix remodelling. However, in chronic wounds it is found that MMP-9 levels 
remain persistently elevated and is thought to be responsible for the degradation of matrix 
and cell growth promoting agents in chronic wounds (Widgerow, 2011). The researchers 
concluded that the aqueous extract and flavonoids from fir honey dew honey are anti-
inflammatory and their ability to suppress TNFα induced MMP-9 production by human 
keratinocytes may explain the therapeutic effects of honey in the treatment of chronic 
wounds.   
Ranzato, Martinotti & Burlando (2013) reported that acacia and buckwheat honey (purchased 
from an apiculture centre in Japan) upregulated IL-4 and IL-8 production and decreased 
MMP production in human dermal fibroblasts. These honeys were also shown to have 
chemoattractant properties and stimulated wound repair of human dermal fibroblasts in vitro.  
Several studies have reported that ability of honey to promote faster re-epithelialisation rates 
in skin cells in vitro (Ranzato, Martinotti & Burlando (2012); Barui et al, 2013). 
 
11 
 
Immunomodulatory properties of honey: in vivo studies 
To the best of our knowledge there are no studies to date investigating the effects of honey 
specifically on the skin immune system of humans in vivo but such studies are recommended. 
Some suggestions would be to investigate the effects of honey on contact hypersensitivity or 
delayed type hypersensitivity responses induced in humans in vivo. There are studies 
investigating the efficacy of honey in the treatment of skin disorders including wounds, of 
which the effects may be caused by the in vivo immunomodulatory properties of honey 
(Naidoo et al, 2011; Jull et al, 2015). For example, a honey mixture (containing honey, 
beeswax and olive oil) was found to significantly improve the symptoms of atopic dermatitis, 
seborrheic dermatitis, psoriasis, pityriasis versicolor and tinea cruris (Al-Waili, 2001; 2003; 
2004). 
An animal study worthy of note is that by Choi et al (2014) which provided evidence that a 
topical herbal honey and chitosan cream formulation reduced symptoms in atopic dermatitis 
like lesions induced in vivo in mice. The lesions were induced with 2, 4 dinitrochlorobenzene 
(DNCB), a contact sensitiser. The honey was obtained from hives in Mount Jiri, Korea. 
Serum IgE, IL-4 and IL-12 levels as well as dermal mast cell infiltration were also reduced in 
the honey/chitosan treated group.  
Discussion  
It can be concluded from the aforementioned in vitro research that honeys from a variety of 
origins have immunomodulatory properties. These effects have been shown to be both 
immunostimulatory and anti-inflammatory and such opposing results may be due to the 
complex nature of the composition of different kinds of honey and also to differences in cell 
types used and parameters measured across studies. The scientific evidence suggests that 
honey can stimulate the production of immunological mediators such as cytokines that play 
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an important role in the early wound healing process and downregulate the production of 
molecules e.g. MMPs and ROIs that contribute to excessive inflammation in the chronic 
wound (see Figure 1). In a review paper by Majtan (2014) the author speculates that honey 
stimulates cytokine and MMP production from keratinocytes when there is a low level of 
inflammation e.g. in a non-infected wound. When a wound is infected and there is a high 
level of inflammation the authors suggest that honey suppresses the production of 
inflammatory cytokines and MMPs by keratinocytes. In the majority of studies, researchers 
have made extrapolations from their findings in relation to honey as a treatment for wounds, 
most likely because of the clinical use of honey in wound healing today. There are, however, 
other skin disorders with an immunological aetiology e.g. atopic dermatitis and psoriasis that 
respond to topical immunomodulating agents such as steroids and immunosuppressive UV 
therapy. As research has identified honey as an immune modulating agent, it is logical to 
consider honey as a potential therapeutic agent for other immune mediated skin disorders. 
However, due to the complex nature of the immune system in skin disease, it may be difficult 
to infer what effects honey will have on such conditions without further investigation. The 
cytokines TNF-α, IL-18 and IL-8 are pro-inflammatory cytokines that contribute to the 
pathology of inflammatory skin disorders, whilst IL-10 on the other hand, is an 
immunosuppressive cytokine capable of down-regulating inflammation (Numerof and 
Asadullah, 2006; Noh and Lee, 2012). TNF-α, IL-18 and IL-8 have also been shown to play a 
role in wound healing (Kanno et al, 2013; Kampfer et al, 2000; Jiang, Sanders, Ruge & 
Harding, 2012). An investigation into the ability of honey to modulate the production of such 
cytokines by skin cells would help determine if honey has immunosuppressive, immune 
stimulatory or wound healing properties that may contribute to skin healing. Antimicrobial 
peptides (AMPs) such as Cathelicidin LL-37 and hBD-2 not only function as antimicrobials 
protecting skin from pathogenic microbes such as Staphylococcus aureus but also as 
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immunomodulators (Li, Xiang, Zhang, Huang & Su, 2012). LL-37 has also been shown to 
contribute to cutaneous wound healing by stimulating re-epithelialization (Heilborn et al, 
2003). An investigation into the ability of honey to modulate AMP production would 
determine if honey is able to affect wound healing or the skin immune response against 
pathogenic microbes. Additionally, the production of AMPs is thought to be perturbed in 
certain inflammatory skin disorders; increased in psoriasis and decreased in eczema 
(Nakatsuji and Gallo, 2012). The ability of honey to modulate AMP production may 
contribute to skin homeostasis in such skin disorders.  The immunomodulatory properties of 
honey may also have relevance in the fight against skin cancer, particularly as the immune 
system plays an important role in preventing the outgrowth of transformed tumours.  
 
The components in honey responsible for its in vitro immunomodulatory properties have not 
been fully identified but have been attributed to lipopolysaccharide, a 5.8kDa component, 
major royal jelly protein 1, arabinogalactans, polyphenols and antioxidants. Production of 
reactive oxygen intermediates (ROIs) are an important cause of excessive inflammation 
because they can induce oxidative activation of NF-κB, leading to the production of pro-
inflammatory mediators (Novo and Parola, 2012). It has been proposed that antioxidants can 
reduce inflammation via inhibition of NFκB activation.  Chepulis and Francis (2012) 
however did not find a direct correlation with the total antioxidant levels and anti-
inflammatory results although antioxidant levels were found to be high in the honeys they 
tested. It therefore may be that antioxidants are not the sole anti-inflammatory agents present 
in honey.  
The immunomodulatory properties of honey are complex and not yet fully understood. 
Despite the interesting findings to date, it is evident that further research is necessary for a 
14 
 
fuller understanding of the ability of honey to modulate the skin immune system, particularly 
in vivo, and to establish how such properties may be utilised clinically for the amelioration of 
skin disease. As well as the complex nature of honey itself, it is likely that the 
microenvironment of the skin disorder will have a major influence on the efficacy of honey in 
clinical practice. A more complete identification of the immunomodulatory components in 
honey may be useful for the development of novel immunotherapeutic agents. It may be that 
honey exerts synergistic therapeutic effects when combined with other agents and this would 
be an area worth exploring. As with the antimicrobial properties of honey, innovative 
research that can maximally exploit the immunomodulatory properties of honey may in the 
future lead to the manufacturing of a product that is highly valued in dermatology.  Also, with 
the wide variety of honeys being produced worldwide it may be that some have superior 
immune modulating properties that are yet to be discovered. As our scientific knowledge of 
honey advances it seems that the properties of this natural substance are becoming more and 
more remarkable.  
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Table 1. Percentage inhibition of TNF-α production by neutrophils incubated with manuka 
honey samples with different methylglyoxal (MGO) content. Manuka honey samples were 
obtained from Waiarapa region of New Zealand.  (Results from Chepulis & Francis, 2012).  
Manuka Honey Sample % Inhibition of Production of Tumour 
Necrosis Factor-alpha (TNF-α) by 
Neutrophils  
MGO 250
TM  100 μg/ml -30.2% 
MGO 250
TM  400 μg/ml +29.9% 
MGO 400
TM 
 100 μg/ml +15.3% 
MGO 400
TM  400 μg/ml +19.5% 
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Figure 1. Possible mechanisms by which the immunomodulatory properties of honey could 
enhance the healing of both acute and chronic wounds. ( - increased, - reduced).  
 
